Covid-19 is not the only disease that scientists are trying to cure right now. Investors were reminded of that last week when Biogen’s Alzheimer’s medicine received a boost from reviewers in the U.S. Food and Drug Administration, ahead of Friday’s meeting. outside experts. The panel of experts then voted – 10 to 0 – that the Biogen studies did not prove the drug’s effectiveness.
Investors should think twice before buying Biogen shares to go higher.